Table 2. Initial medication after HTX.
| Parameter | PPM (n=36) | No PPM (n=585) | Difference | 95% CI | P value |
|---|---|---|---|---|---|
| Cyclosporine A, n (%) | 22 (61.1) | 322 (55.0) | 6.1 | −10.3–22.5 | 0.48 |
| Tacrolimus, n (%) | 14 (38.9) | 263 (45.0) | 6.1 | −10.3–22.5 | 0.48 |
| Azathioprine, n (%) | 19 (52.8) | 245 (41.9) | 10.9 | −5.9–27.7 | 0.20 |
| Mycophenolate mofetil, n (%) | 17 (47.2) | 340 (58.1) | 10.9 | −5.9–27.7 | 0.20 |
| Steroids, n (%) | 36 (100.0) | 585 (100.0) | 0.0 | NA | NA |
| Acetylsalicylic acid, n (%) | 3 (8.3) | 61 (10.4) | 2.1 | −7.3–11.5 | 0.69 |
| Beta blocker, n (%) | 6 (16.7) | 106 (18.1) | 1.4 | −11.2–14.0 | 0.83 |
| Ivabradine, n (%) | 2 (5.6) | 52 (8.9) | 3.3 | −4.5–11.1 | 0.49 |
| Calcium channel blocker | 12 (33.3) | 153 (26.2) | 7.1 | −8.7–22.9 | 0.34 |
| ACE inhibitor/sartan, n (%) | 18 (50.0) | 256 (43.8) | 6.2 | −10.6–23.0 | 0.46 |
| Diuretic, n (%) | 36 (100.0) | 585 (100.0) | 0.0 | NA | NA |
| Statin, n (%) | 11 (30.6) | 228 (39.0) | 8.4 | −7.2–24.0 | 0.31 |
| Gastric protection (PPI/H2 blocker), n (%) | 36 (100.0) | 585 (100.0) | 0.0 | NA | NA |
ACE inhibitor, angiotensin-converting-enzyme inhibitor; CI, confidence Interval; HTX, heart transplantation; H2 blocker, histamine receptor blocker; n, number; NA, not applicable; PPI, proton pump inhibitor; PPM, permanent pacemaker.